Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P)

Exclusion Criteria

• •Patients must not have known hypersensitivity to GSK2636771 or compounds of similar chemical or biologic composition
• •Patients must not have tumors harboring co-existing aberrations activating the PI3K/MTOR and MAPK pathways, such as PIK3CA, PIK3R1, BRAF, KRAS and AKT1, TSC1/2, mTOR, NF2, NRAS, HRAS, NF1
• •Patients must not have received prior treatment with agents targeting the PI3K beta, AKT, or mTOR:
• •* This includes (but is not limited to):
• •* mTOR inhibitors: temsirolimus, everolimus, ridaforolimus, sirolimus, salirasib, CC-223, INK128, DS-3078, CC-115, AZD-2014
• •* Dual PI3K/mTOR inhibitors: BEZ235, XL-765, GDC 0980, PF-04691502, GSK 2126458, Quinacrine, PKI-587, P-P7170, LY3023414, GDC 0084, DS 7423, CBLC-137
• •* Pan-PI3K inhibitors: BKM-120 (buparlisib), PX-866, XL-147, GDC-0941 (pictilisib), BAY-806946, ZSTK-474, WX 037, SRX5000, SRX2523, AMG511, PQR308, BAY 94-9343
• •* PI3K inhibitors with beta isoform activity: prior GSK2636771 is not allowed, nor is GS-9820, PQR3XX, KAR4139
• •* The following previous treatments are allowed:
• •* BYL719 (PI3Kalpha inhibitor)
• •* GDC-0032 (PI3Kalpha inhibitor)
• •* INK1117 (PI3Kalpha inhibitor)
• •* Idelalisib (PI3Kdelta inhibitor)
• •* IPI-125 (PI3K gamma delta inhibitor)
• •* TGR1202 (PI3Kdelta inhibitor)
• •* SRX2558 (PI3Kdelta inhibitor)
• •* RP6530 (PI3K gamma delta inhibitor)
• •* PWT143 (PI3Kdelta inhibitor)
• •* IPI443 (PI3K gamma delta inhibitor)
• •* GNE293 (PI3Kdelta inhibitor)
• •Patients with a history of interstitial lung disease or pneumonitis are excluded
• •Patients must not have any congenital platelet function defects and cannot be on any of the following anti-platelet drugs: clopidogrel, ticlopidine, prasugrel, that act at platelet purinergic receptors
• •* Any need for starting anti-platelet therapy in a patient enrolled to this arm will have to be evaluated by the subprotocol chair